CMMB - Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference | Benzinga
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation—
—New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis—
TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy. Chemomab also announced a poster presentation at the Gordon Research Conference on Chemotactic Cytokines, held June 2-7, 2024 in Portland, Maine.
The presentations cover a range of topics, from new preclinical studies further elucidating the roles of the novel soluble protein target CCL24 and Chemomab's CCL24-neutralizing antibody CM-101 in fibro-inflammatory liver disorders, to translational research supporting the clinical development of CM-101 for PSC, a rare and often fatal liver disease.
The first EASL poster describes an ex vivo-developed translational assay designed to further characterize the anti-fibrotic activity of CM-101 in patients with liver disease.1 This study was selected for an EASL 2024 Poster Tour highlighting presentations of special interest. Using a serum-based ex vivo hepatic stellae cell (HSC) activation assay derived from patients with liver fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH), the study showed that sera from these patients directly activates HSCs and that HSC activation levels were significantly reduced in the sera of patients treated with CM-101. Importantly, a protein signature generated from CCL24-activated HSCs was able to predict PSC disease and its severity. These findings support CM-101's mode of action in liver fibrosis and are expected to help in characterizing its anti-fibrotic drug effects by serving as a translational tool in PSC clinical trials.
In a second poster2, researchers presented a comprehensive proteomic profiling study of patients with PSC, which was combined with machine learning-based methods to develop a protein signature model that successfully predicted the presence and severity of PSC when combined with proteins correlated with the Enhanced Liver Function (ELF) ...